Pfizer's Ibrance clears first hurdle to early access in U.K.

Pfizer's ($PFE) new cancer standout, Ibrance, has taken its first step toward joining the U.K.'s Early Access to Medicines program, winning the "promising innovative medicine" tag from the country's Medicines and Healthcare Regulatory Agency. Since scoring a quick FDA approval last February, the breast cancer-fighter--green-lighted for patients with tumors that are estrogen-receptor-positive but HER2-negative--has been tearing it up in the marketplace. In Q3, Ibrance netted $230 million in sales, burying the $195 million analysts expected. Report

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Johnson & Johnson is chasing giants in its play for psoriatic arthritis with Tremfya. Strong data could help the newcomer convince the FDA.

Besting AbbVie's megablockbuster Humira is no laughing matter, but now Eli Lilly's Taltz has doubled up on head-to-head wins.